Secondary hyperparathyroidism is an endocrine and metabolic condition in which increased PTH represents an adaptive response to a chronic stimulus that reduces the availability of ionized calcium or alters phosphate balance. Unlike primary hyperparathyroidism, in which parathyroid secretion is autonomous, PTH increases in secondary hyperparathyroidism to compensate for an upstream disturbance, with the physiological aim of stabilizing serum calcium and maintaining mineral homeostasis. The most clinically relevant setting is chronic kidney disease (CKD), in which secondary hyperparathyroidism occurs within the spectrum of chronic kidney disease-mineral and bone disorder, but the same adaptive mechanism may also develop in vitamin D deficiency, malabsorption and conditions in which calcium intake or absorption is insufficient.
Its clinical impact arises because an adaptive response that is beneficial in the short term becomes harmful when it persists. Chronic exposure to elevated PTH alters bone remodeling, increases the risk of fractures and contributes to a vascular environment that promotes calcification, particularly in patients with kidney failure. From this perspective, the problem is not limited to the PTH value itself, but includes its trajectory over time and the way in which calcium, phosphate, vitamin D and renal function interact to determine skeletal and cardiovascular risk.
The epidemiology of secondary hyperparathyroidism is closely associated with the prevalence of conditions that produce chronic stimulation of the parathyroid glands. Overall, the predominant cause is CKD (chronic kidney disease), with a frequency that progressively increases as glomerular filtration declines and becomes particularly relevant in advanced stages and among patients undergoing dialysis. CKD progression alters phosphate balance and the ability of the kidney to produce calcitriol, creating the biological basis for increased PTH secretion. Secondary hyperparathyroidism is therefore one of the most common endocrine complications encountered in nephrology and a central component of skeletal and cardiovascular risk in patients with uremia.
Epidemiologically significant settings also exist outside CKD. Vitamin D deficiency is highly prevalent in the general population and may sustain an adaptive increase in PTH, particularly when calcium intake is low or when reduced sunlight exposure, advanced age, obesity or chronic disease coexist. Intestinal malabsorption, inflammatory bowel disease, uncontrolled coeliac disease and bariatric surgery may reduce calcium and vitamin D absorption, creating a chronic stimulus that promotes secondary hyperparathyroidism and accelerated bone loss. Certain pharmacological treatments may also contribute, particularly in vulnerable patients, when they interfere with intestinal absorption, vitamin D metabolism or calcium balance.
In CKD, risk factors are not limited to the glomerular filtration rate. Hyperphosphatemia or phosphate levels in the high-normal range, inadequate correction of vitamin D status, excessive or insufficient calcium within the overall balance and chronic inflammation influence the PTH trajectory and promote progression towards forms that are more difficult to control. Over time, persistent stimulation induces parathyroid hyperplasia and reduces sensitivity to calcium and vitamin D, making medical control less effective. This mechanism explains why secondary hyperparathyroidism becomes increasingly common with longer duration of advanced CKD, particularly in dialysis.
Individual vulnerability also depends on comorbidities and organ reserve. Advanced age, diabetes, malnutrition, frailty and conditions that increase the risk of falls amplify the impact of accelerated bone remodeling. From a cardiovascular perspective, atherosclerosis, hypertension and disturbances of mineral metabolism increase the likelihood of clinically significant vascular calcification, making secondary hyperparathyroidism a risk multiplier rather than a simple biochemical abnormality.
In summary, the distribution of this disorder reflects the prevalence of CKD and vitamin D deficiency, but clinical severity is determined by the chronicity of the stimulus and by the way mineral metabolism is reorganized in the presence of kidney failure or reduced intestinal absorption. Its epidemiological interpretation must therefore extend beyond PTH and integrate renal function, phosphate and vitamin D as major determinants of risk.
Under physiological conditions, PTH secretion is regulated primarily by ionized calcium through the calcium-sensing receptor (CaSR), and in an integrated manner by active vitamin D through the vitamin D receptor. When calcium tends to decrease or intestinal absorption is insufficient, PTH increases to restore serum calcium. It enhances renal calcium reabsorption, promotes calcium release from bone by modulating remodeling and stimulates renal production of calcitriol, thereby increasing intestinal absorption. Secondary hyperparathyroidism develops when this regulatory circuit is persistently activated by an unresolved chronic stimulus.
In the setting of CKD, pathogenesis is multifactorial and progressive. Reduced glomerular filtration limits phosphate excretion, producing a tendency towards retention and a positive phosphate balance. Even before overt hyperphosphatemia develops, phosphate promotes an increase in FGF23, a phosphaturic signal that attempts to preserve mineral balance. However, increased FGF23 reduces renal calcitriol production by inhibiting 1-alpha-hydroxylase, resulting in decreased intestinal calcium absorption and contributing to an environment that stimulates PTH secretion. At the same time, progression of CKD directly reduces the kidney’s ability to produce calcitriol, further weakening endocrine control of calcium homeostasis.
The pathophysiology also includes qualitative changes within the parathyroid glands. Chronic stimulation initially induces diffuse parathyroid hyperplasia and, in advanced disease, nodular hyperplasia, together with reduced expression of CaSR and the vitamin D receptor. This shifts the PTH suppression set point and makes the gland less sensitive to feedback signals, promoting progressively higher PTH levels and increasing the difficulty of achieving control with medical treatment. This transition is central to understanding why some patients with advanced CKD develop severe and refractory disease despite interventions targeting phosphate and vitamin D.
At skeletal level, elevated PTH increases turnover and may produce a high-turnover form of renal osteodystrophy, characterized by increased resorption and disruption of bone microarchitecture. In patients with CKD, this develops within a broader framework that may also include defective mineralization, abnormalities of bone volume and alterations in bone quality that are not fully captured by bone densitometry alone. The clinical result is an increased risk of fractures, bone pain and reduced strength, particularly when the disorder is prolonged and inadequately controlled.
At cardiovascular level, the mineral environment associated with CKD promotes vascular and valvular calcification. Elevated phosphate induces osteogenic transformation of vascular smooth muscle cells and contributes to arterial stiffness, ventricular hypertrophy and increased cardiovascular risk. In this setting, secondary hyperparathyroidism is not an isolated causal factor but a component of a pathogenic network in which phosphate, calcium, FGF23 and PTH influence one another, with clinical outcomes determined by the overall balance and duration of exposure.
Outside CKD, pathogenesis is often more straightforward. In vitamin D deficiency and malabsorption, reduced intestinal calcium absorption sustains a compensatory increase in PTH. Over time, this accelerates bone remodeling and may contribute to bone loss and fractures, particularly when the cause is not corrected and additional risk factors coexist. In every setting, the pathophysiological sequence begins as an adaptive response that becomes a source of organ damage when it persists.
The clinical manifestations of secondary hyperparathyroidism depend on the underlying cause and duration of stimulation, and are often dominated by consequences affecting bone, muscle and the cardiovascular system rather than by specific symptoms. In the early stages, particularly in moderate CKD or vitamin D deficiency, patients may have few or no symptoms and the disorder is identified through biochemical assessment of mineral metabolism. As CKD progresses or vitamin D deficiency persists, signs related to accelerated bone remodeling and impaired mineralization may emerge.
During the medical history, reported symptoms may include diffuse or localized bone pain, easy fatigability, cramps and proximal muscle weakness, with reduced functional performance. In patients with advanced CKD, pruritus, sleep disturbances and nonspecific symptoms that overlap with the uremic syndrome may occur, making it difficult to attribute any single symptom exclusively to PTH. A history of low-energy fractures, loss of height or back pain should be regarded as clinically significant, because bone may be fragile in CKD even when bone density does not appear severely reduced.
Muscular manifestations are important because they increase the risk of falls. Weakness, instability and reduced muscle mass, particularly in patients undergoing dialysis or affected by malnutrition, amplify fracture risk and impair quality of life. Secondary hyperparathyroidism may also contribute to chronic pain and reduced exercise tolerance, affecting independence and activities of daily living.
The physical examination may reveal bone tenderness, reduced proximal muscle strength and signs of physical deconditioning. In patients with advanced CKD, clinical evaluation should also include signs of volume overload, vascular abnormalities and complications associated with calcification, although many calcifications remain clinically silent until advanced stages. Bone deformities are less common today than in the past, but may still occur in severe and prolonged disease, particularly when mineral metabolism has remained inadequately controlled for a long period.
In vitamin D deficiency or malabsorption, the clinical picture may be more clearly centered on osteomalacia or bone loss, with pain, weakness and increased susceptibility to fractures. Correction of the underlying cause may improve these manifestations, although functional recovery takes time and often requires nutritional and rehabilitative support.
Overall, secondary hyperparathyroidism is often clinically silent in its early stages but remains relevant because of its capacity to cause cumulative damage. Clinical findings must therefore always be integrated with biochemical data and a structured assessment of skeletal and cardiovascular risk, particularly in patients with CKD.
Secondary hyperparathyroidism should be suspected when PTH is elevated in a setting consistent with compensatory stimulation, particularly when serum calcium is normal or low and abnormalities of phosphate or vitamin D coexist. In clinical practice, the most typical scenario is a patient with CKD whose PTH progressively increases as glomerular filtration declines, often together with phosphate levels in the high-normal or elevated range and reduced calcitriol levels. Even in the absence of symptoms, a rising PTH trajectory in a patient with CKD should prompt a comprehensive assessment of mineral metabolism.
Outside nephrology, secondary hyperparathyroidism should be suspected when elevated PTH is associated with reduced 25-OH-vitamin D, insufficient calcium intake or conditions causing malabsorption. A history of bariatric surgery, chronic diarrhea, uncontrolled coeliac disease or treatments that interfere with absorption and mineral metabolism should strengthen the suspicion. In these cases, interpreting PTH elevation as an adaptive response is consistent with a serum calcium level that is not elevated, and the diagnostic priority is to identify and correct the underlying cause.
Clinical suspicion should also increase when unexplained skeletal or muscular complications arise, including fragility fractures, persistent bone pain, proximal weakness, cramps and reduced physical performance. In patients with CKD, the association of pain, pruritus, functional decline and abnormalities of mineral metabolism should prompt systematic evaluation within the CKD-MBD framework, because elevated PTH may represent only one component of a broader pathophysiology that also involves phosphate, calcium and calcification.
It is equally important to recognize cases in which elevated PTH is not secondary. Elevated PTH associated with hypercalcemia suggests primary or tertiary hyperparathyroidism, while elevated PTH and hypercalcemia in advanced CKD may indicate progression towards a more autonomous form. When biochemical findings are inconsistent with a simple adaptive response, assessment must be expanded and conducted carefully to avoid misclassification and inappropriate treatment strategies.
The diagnosis of secondary hyperparathyroidism is based on the demonstration of elevated PTH in a clinical and biochemical context compatible with compensatory stimulation. Diagnostic assessment must always integrate calcium, phosphate and vitamin D status, because the significance of PTH changes substantially according to these parameters and renal function. In patients with CKD, PTH measurement must be interpreted in light of biological and analytical variability, with greater emphasis placed on the trend over time than on a single isolated value, because clinical decisions depend on persistence and progression.
Initial assessment includes serum calcium and, when required, ionized calcium, phosphate, alkaline phosphatase, creatinine with estimated glomerular filtration rate and 25-OH-vitamin D. Vitamin D should be measured because deficiency is one of the most common causes of adaptive PTH elevation and because its correction changes the trajectory of the condition. In patients with advanced CKD, alkaline phosphatase provides an indirect estimate of bone turnover activity in a setting in which densitometry alone may not capture bone quality or the specific form of renal osteodystrophy.
Diagnostic assessment of secondary hyperparathyroidism
In CKD, the diagnostic objective is not merely to label an elevated PTH value, but to define the patient’s position along the CKD-MBD continuum. Nephrology guidelines therefore recommend an approach based on serial assessment of calcium, phosphate and PTH, with interventions guided by trends and correction of modifiable factors, particularly hyperphosphatemia and vitamin D deficiency. Within this framework, markedly and persistently elevated PTH, especially in dialysis, suggests advanced parathyroid hyperplasia and reduced sensitivity to feedback signals, with more complex therapeutic implications.
In forms unrelated to CKD, diagnosis requires identification of the cause of reduced absorption or reduced availability of calcium and vitamin D. Nutritional and gastroenterological assessment, when indicated, forms an integral part of the diagnostic process. In these patients, correction of the underlying cause generally leads to progressive normalization of PTH, whereas persistent elevation after adequate correction requires reassessment and exclusion of alternative diagnoses.
Parathyroid imaging is not required for the diagnosis of secondary hyperparathyroidism. It becomes relevant only in selected scenarios, such as preoperative planning for advanced and refractory disease, but it does not replace biochemical diagnosis and should not precede comprehensive assessment of mineral metabolism. Correct diagnosis is based on the integration of physiology, laboratory trends and clinical context.
The classification of secondary hyperparathyroidism is primarily etiological and distinguishes forms associated with CKD from those caused by vitamin D deficiency, malabsorption or insufficient calcium intake. This distinction is essential because in CKD the disorder is part of a broader systemic process, whereas in other forms correction of the underlying cause may resolve the condition and rapidly reduce parathyroid stimulation. Even within CKD, the stage of kidney disease influences pathophysiology and treatment, because the roles of phosphate, calcitriol and calcimimetics differ substantially between early stages and dialysis.
A clinically useful classification also considers the mineral profile and response to treatment. In early CKD, PTH may increase while phosphate remains within the reference range and serum calcium is normal, reflecting early adaptations partly mediated by FGF23. With progression, hyperphosphatemia, reduced calcitriol and a more marked increase in PTH become more likely. Severity therefore cannot be defined by a single value, but depends on persistence, increase over time and consistency with calcium and phosphate levels. Rising PTH despite adequate phosphate control suggests more advanced hyperplasia and reduced sensitivity to feedback mechanisms.
A further level of classification concerns skeletal risk. Persistently elevated PTH tends to be associated with high-turnover renal osteodystrophy, but low-turnover conditions may also coexist in CKD, particularly in the presence of excessive PTH suppression or additional contributing factors. Severity must therefore also be interpreted through turnover markers such as alkaline phosphatase and through the clinical history of fractures, bone pain and fragility, rather than through PTH alone.
Finally, in patients with advanced CKD, progression towards more autonomous disease is clinically important. When secondary hyperparathyroidism is prolonged and refractory, the gland may further lose sensitivity to calcium and vitamin D, and hypercalcemia may develop in some cases, suggesting a more autonomous condition. This scenario no longer represents a simple adaptive response and requires a more aggressive and often multidisciplinary therapeutic approach.
Treatment of secondary hyperparathyroidism aims to reduce chronic stimulation of the parathyroid glands by correcting abnormalities of mineral metabolism and preventing skeletal and cardiovascular complications. In CKD, treatment forms an integral part of CKD-MBD management and requires a balance between phosphate control, maintenance of safe serum calcium levels and optimization of vitamin D status. The strategy is guided by persistence and the trend of PTH over time, because interventions based on single values may result in excessive correction and adverse consequences such as hypercalcemia or excessive suppression of bone turnover.
Reducing the phosphate burden is a cornerstone of treatment. This includes individualized dietary measures, with attention to the quality of protein sources and the presence of phosphate additives, together with phosphate binders when indicated. The choice between calcium-containing and non-calcium-containing binders depends on serum calcium, calcification risk and overall calcium balance, because excessive calcium exposure may promote vascular calcification, particularly in advanced CKD. Phosphate control reduces one of the main drivers of PTH secretion and improves the overall mineral profile.
Vitamin D management is equally important. Correction of deficiency with cholecalciferol or ergocalciferol is indicated when 25-OH-vitamin D levels are low, with monitoring of calcium and phosphate. In advanced CKD, reduced calcitriol production may require active vitamin D or selective vitamin D receptor activators, particularly when PTH is elevated and progressively rising. These treatments may increase serum calcium and phosphate, so their use must be individualized and integrated with the phosphate-control strategy.
In patients undergoing dialysis or those with more severe disease, calcimimetics provide an effective option for reducing PTH by increasing CaSR sensitivity. They may lower both PTH and serum calcium, making them particularly useful when active vitamin D is limited by hypercalcemia or hyperphosphatemia. Their use requires monitoring of serum calcium to prevent hypocalcemia and preserve mineral balance, because excessive correction may have clinical and skeletal consequences. In selected situations, calcimimetics and active vitamin D are combined to achieve more stable control while balancing their effects on calcium and phosphate.
When secondary hyperparathyroidism is severe and refractory, particularly in the presence of advanced hyperplasia and inadequate control despite optimized treatment, parathyroidectomy becomes an option. The indication is based on the risk of complications, persistence of markedly elevated values and clinical effects such as pruritus, bone pain, fractures and calcification, with the aim of definitively reducing the hormonal burden and improving quality of life and mineral control. Perioperative management requires careful attention to the risk of hypocalcemia and hungry bone syndrome, particularly in patients with high bone turnover and skeletal mineral depletion.
Outside CKD, treatment focuses on correction of the underlying cause. In vitamin D deficiency and insufficient calcium intake, supplementation and dietary optimization reduce the stimulus and progressively normalize PTH. In malabsorption, management requires treatment of the underlying disorder and often higher doses or specific formulations, with monitoring of serum calcium and turnover markers. In every setting, effective treatment interrupts the pathophysiological sequence rather than merely reducing the numerical PTH value.
Follow-up of secondary hyperparathyroidism is essential because the disorder is dynamic and closely linked to progression of the underlying cause, particularly CKD. Monitoring should include serial assessment of serum calcium, phosphate and PTH, integrated with renal function and vitamin D status. In CKD, nephrology guidelines emphasize an approach based on trends and progressive correction of modifiable factors, avoiding fluctuations and interventions guided by isolated values that may induce hypercalcemia or other mineral disturbances.
The frequency of monitoring depends on the stage of CKD and stability of the mineral profile. In patients with moderate CKD and stable parameters, testing may be performed at longer intervals, whereas advanced CKD and dialysis require closer monitoring because phosphate binders, active vitamin D and calcimimetics often need titration. Alkaline phosphatase is useful as an indirect estimate of bone turnover activity, particularly when PTH is markedly elevated or when therapeutic changes may rapidly modify skeletal dynamics.
Follow-up should also address complications. Surveillance of fracture risk and skeletal fragility is essential because CKD increases fracture risk through mechanisms that are not fully explained by bone density. In patients with skeletal symptoms or fractures, assessment must be integrated and coordinated with nephrology, particularly when anti-osteoporotic therapy is being considered in the presence of impaired renal function. Cardiovascular surveillance is also relevant because phosphate and calcification contribute to vascular stiffness and overall cardiovascular risk.
In patients treated with calcimimetics or active vitamin D, follow-up must be designed to identify hypocalcemia or hypercalcemia at an early stage and maintain a balance that reduces PTH without promoting calcification. The quality of monitoring is reflected in the ability to preserve mineral stability over time and avoid cycles of excessive correction that may shift the patient towards a different risk, such as excessively low bone turnover or excessive calcium exposure.
In forms unrelated to CKD, follow-up verifies correction of the underlying cause and progressive normalization of PTH, with monitoring of vitamin D, serum calcium and, when indicated, bone turnover markers. Persistent PTH elevation despite adequate correction requires diagnostic reassessment because it may indicate an unrecognized cause or a condition other than classic secondary hyperparathyroidism.
The prognosis of secondary hyperparathyroidism depends mainly on the reversibility of the underlying cause and the duration of exposure to elevated PTH. In forms associated with vitamin D deficiency or reduced calcium intake, prognosis is generally favorable when correction is timely and maintained, with progressive normalization of PTH and improvement in skeletal status. In forms associated with CKD, prognosis is more complex because the disorder is closely linked to the progression of kidney disease and overall cardiovascular risk.
The main complications involve the skeleton. Sustained PTH excess increases bone turnover and promotes high-turnover renal osteodystrophy, with an increased risk of fractures, bone pain and deterioration of bone quality. In patients with CKD, skeletal fragility is multifactorial and may persist even after partial PTH control. Skeletal prognosis therefore requires an integrated approach that includes nutrition, physical activity, fall prevention and optimization of mineral metabolism.
From a cardiovascular perspective, elevated phosphate and vascular and valvular calcification are major prognostic determinants. The pro-calcific environment of CKD contributes to arterial stiffness, ventricular hypertrophy and increased risk of cardiovascular events. Secondary hyperparathyroidism forms part of this broader pathogenic axis, but its control, together with phosphate management, remains relevant for limiting progression of calcification and improving mineral stability.
Additional clinical complications include uremic pruritus, chronic pain, reduced physical performance and, in severe and prolonged disease, increased vulnerability to adverse outcomes associated with malnutrition and frailty. In advanced CKD, uncontrolled mineral abnormalities may contribute to a substantial symptom burden and reduced quality of life, making PTH control a functional objective rather than a purely laboratory-based target.
Treatment-related complications depend on the balance achieved. Phosphate binders and active vitamin D may promote hypercalcemia or increase calcium exposure, whereas calcimimetics may cause hypocalcemia. When required, parathyroidectomy carries a risk of hypocalcemia and hungry bone syndrome and requires careful postoperative management. Within a structured care pathway, these risks can be prevented or managed, and prognosis improves when mineral control is stable and consistent with the patient’s residual physiology.
Overall, secondary hyperparathyroidism is a condition with potentially substantial clinical impact because it reflects and amplifies the severity of the underlying cause, particularly CKD. Prognosis is better when the disorder is identified early, treated with strategies that correct phosphate and vitamin D abnormalities, and monitored over time with careful attention to trends, thereby limiting progression and skeletal and vascular complications.